Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primaquine with artemether-lumefantrine versus dihydroartemisinin-piperaquine for Plasmodium vivax malaria in the Solomon Islands
ACTRN12617000329369Phase 4Completed
- Sponsor
- WEHI
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of primaquine, artemether + lumefantrine and dihydroartemisinin + piperaquine in vivax malaria (3 arms), sponsored by WEHI. Primary endpoint: Primary efficacy endpoint. Started Sep 2017; status: completed.
02
Drugs
primaquineartemether + lumefantrinedihydroartemisinin + piperaquine
03
Conditions
vivax malaria
Beyond the preview
Go deeper on ACTRN12617000329369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000329369.